OrbiMed Exits PMV Pharmaceuticals Stake, Selling $8.06M in Shares
Summary
OrbiMed Advisors and OrbiMed Capital GP V LLC have fully exited their position in PMV Pharmaceuticals, Inc., selling approximately $8.06 million worth of common stock and ceasing to be a beneficial owner of more than 5% of the company.
Key Events
-
Major Investor Exit
OrbiMed Advisors and OrbiMed Capital GP V LLC reported ceasing to be beneficial owners of more than 5% of PMV Pharmaceuticals, Inc., marking an exit filing.
-
Significant Share Sales
OrbiMed sold a total of 4,975,291 shares of common stock on February 27, 2026, and March 2, 2026, at a price of $1.62 per share, totaling approximately $8.06 million.
-
Full Liquidation of Position
The filing indicates a complete divestment of OrbiMed's previously held stake, representing a substantial portion of the company's outstanding shares.
Analysis
This Schedule 13D/A filing indicates a significant divestment by OrbiMed, a major institutional investor. The sale of approximately 4.98 million shares, valued at over $8 million, represents a substantial portion of PMV Pharmaceuticals' outstanding stock and signals a complete liquidation of OrbiMed's position. Such a large-scale exit by a prominent investor can be interpreted negatively by the market, potentially raising concerns about the company's future prospects or OrbiMed's investment thesis. Investors should monitor for any further institutional ownership changes or company-specific news that might explain this divestment.
At the time of this filing, PMVP was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.81 to $1.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.